YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS



    MISSISSAUGA, ON, May 14 /CNW/ - YM BioSciences Inc. (NYSE Amex:  YMI,
TSX:YM, AIM:YMBA), a life sciences product development company that identifies
and advances a diverse portfolio of promising cancer-related products at
various stages of development, today reported operational and financial
results for the third quarter of fiscal 2009, ended March 31, 2009.
    "Just a few days ago we reported critically important data at the 100th
AACR conference in Denver highlighting the mechanistic differences between
nimotuzumab and the EGFR targeting antibody, Erbitux(R)," said David Allan,
Chairman and CEO of YM BioSciences. "These data demonstrate that nimotuzumab
is predisposed to bind to cancerous cells with high levels of EGFR on their
surface while ignoring normal cells with low EGFR levels. For the competing
drugs, binding is indiscriminate since they bind to low levels of EGFR and, as
a result, these products cause severe toxicities as they interact with healthy
tissues. With Erbitux(R) as the leading EGFR-targeting drug on the market and
generating more than $1.5 billion in annual sales, these findings are profound
and further define the significant opportunity for our lead product."
    Nimotuzumab is being advanced globally on multiple fronts supported by a
network of cooperative relationships. In total, more than 15 Phase II and
Phase III trials are currently ongoing, ten of which are being conducted by YM
or its licensees. During the third quarter of fiscal 2009:

    
    -   The National Cancer Centre of Singapore (NCCS) selected nimotuzumab
        for evaluation in the adjuvant setting in a multinational Phase III
        trial of more than 700 patients with cancers of the head and neck,
        citing the drug's benign safety profile. The trial is being supported
        by YM licensee, Innogene Kalbiotech Ltd., a subsidiary of the public
        company, Kalbe Farma.
    -   Two of YM's licensees for nimotuzumab, Daiichi-Sankyo Co., Ltd. in
        Japan and Kuhnil Pharmaceutical Co. in Korea, are conducting a Phase
        II randomized, open-label trial evaluating nimotuzumab in patients
        with advanced or recurrent gastric cancer.
    -   YM's licensee in Europe, Oncoscience AG, reported that it continues
        to enroll patients into a randomized Phase III study evaluating
        nimotuzumab in adult glioma patients and into a randomized Phase
        IIb/IIIa trial in patients with advanced pancreatic cancer.
    -   YM and YM USA continued to enroll children with progressive, diffuse,
        intrinsic pontine glioma (DIPG) into a Phase II trial at multiple
        sites in the US, Canada and Israel and recruitment could be completed
        in late calendar 2009 or early 2010.
    

    YM continues to prepare its second late-stage product, AeroLEF(R), for
further development internationally. After consulting with regulatory bodies
in Europe and Canada, the Company is now determining the optimal clinical path
forward and conducting discussions with potential partners.

    Financial Results (CDN dollars)

    Total revenue (out-licensing revenue and interest income) for the third
quarter of fiscal 2009, ended March 31, 2009 was $1.0 million compared with
$1.8 million for the third quarter of fiscal 2008. Total revenue for the first
nine months of fiscal 2009 was $4.8 million compared with $5.5 million for the
first nine months of fiscal 2008. The majority of YM's out-licensing revenue
comes from five out-licensing agreements with third party licensees for
nimotuzumab. The decrease in revenue for the third quarter of fiscal 2009
compared to the same period in the prior year is mainly attributable to a 12
month extension of the revenue recognition period for the initial payment from
one of YM's licensees. The decrease in revenue for the nine months ended March
31, 2009 compared to the same period in the prior year is mainly as a result
of the above mentioned extension and the ending of monthly revenue recognition
for one other deferred revenue contract, partially offset by a milestone
payment received this year from one of the Company's licensees. The Company
also began receiving royalty payments from a limited sales program in Europe
initiated in the fourth quarter of fiscal 2008. Interest income decreased as
the Company draws on its cash balances to fund its operations and due to lower
interest rates.
    General and administrative expenses were $1.2 million for the third
quarter of fiscal 2009 compared with $1.4 million for the third quarter of
fiscal 2008. General and administrative expenses were $3.5 million for the
first nine months of fiscal 2009 compared with $5.5 million for the first nine
months of fiscal 2008. These decreases were mainly a result of stock option
expenses decreasing as well as decreases in legal fees, salaries, consulting
and investor relations expenditures.
    Licensing and product development expenses were $3.3 million for the
third quarter of fiscal 2009 compared with $4.3 million for the third quarter
of fiscal 2008. Licensing and product development expenses were $11.5 million
for the first nine months of fiscal 2009 compared with $12.1 million for the
first nine months of fiscal 2008.
    Costs associated with development activities for nimotuzumab remained at
$1.5 million in the quarter compared to a year ago and increased by $1.1
million to $4.7 million for the nine months ended March 31, 2009. The increase
in expenses is primarily related to preparation for the two new Phase II
trials.
    Costs associated with development activities for AeroLEF(TM) decreased by
$0.2 million to $0.4 million for the three month period ended March 31, 2009
compared to the same period in the prior year. For the nine month period ended
March 31, 2009 costs were $1.6 million, similar to the same period in the
prior year.
    Net loss for the third quarter of fiscal 2009 was $3.5 million ($0.06 per
share) compared to $3.8 million ($0.07 per share) for the same period last
year. Net loss for the first nine months of fiscal 2009 was $9.8 million
($0.18 per share) compared to $11.9 million ($0.21 per share) for the same
period last year.
    As at March 31, 2009 the Company had cash and cash equivalents and
short-term deposits totaling $46.6 million and payables and accrued
liabilities totaling $1.9 million compared to $58.1 million and $2.0 million
respectively at June 30, 2008.
    As at March 31, 2009 the Company had 58,216,309 common shares
outstanding, of which 2,380,953 common shares are held in escrow to be
released contingent upon the completion of certain milestones.

    About YM BioSciences

    YM BioSciences Inc. is a life sciences product development company that
identifies and advances a portfolio of promising cancer-related products at
various stages of development. The Company is currently developing two
late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized
Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of
free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical
trial expertise and a diversified business model designed to reduce risk while
advancing clinical products toward international approval, marketing and
commercialization.
    Nimotuzumab is a humanized monoclonal antibody in development worldwide,
targeting multiple tumor types primarily in combination with radiation and
chemoradiation. It is significantly differentiated from all other currently
marketed EGFR-targeting agents due to its remarkably benign side-effect
profile. Nimotuzumab's anti-tumor activity has led to its approval for
marketing in more than 12 countries. In more than 3,500 patients reported as
having been treated with nimotuzumab worldwide to date, no Grade IV incidents
of radiation dermatitis have been described, severe rash has not been observed
and reports of the other severe side-effects that are typical of
EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's
majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was
developed at the Center of Molecular Immunology. YM is developing AeroLEF for
the treatment of moderate to severe acute pain. The product is differentiated
from other approaches using fentanyl because patients can individually control
the analgesia required for their differing intensities of pain. AeroLEF met
all endpoints in a randomized Phase II trial and is currently being prepared
for late-stage development internationally.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(R) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    
    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars)

    -------------------------------------------------------------------------
                                                    March 31,        June 30,
                                                        2009            2008
    -------------------------------------------------------------------------
                                                  (Unaudited)

    Assets

    Current assets:
      Cash and cash equivalents                $   8,917,872   $   3,119,189
      Short-term deposits                         37,688,943      54,981,737
      Accounts receivable                            280,479         403,371
      Prepaid expenses                               543,664         375,133
    -------------------------------------------------------------------------
                                                  47,430,958      58,879,430

    Property and equipment                           105,268         128,400

    Intangible assets                              3,270,003       4,065,409

    -------------------------------------------------------------------------
                                               $  50,806,229   $  63,073,239
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Liabilities and Shareholders' Equity

    Current liabilities:
      Accounts payable                         $     636,680   $     307,588
      Accrued liabilities                          1,302,123       1,715,024
      Deferred revenue                             2,562,696       4,623,340
    -------------------------------------------------------------------------
                                                   4,501,499       6,645,952

    Deferred revenue                               3,522,556       4,414,256

    Shareholders' equity:
      Share capital                              172,921,153     172,921,153
      Share purchase warrants                              -       3,150,539
      Contributed surplus                         12,848,942       9,123,824
      Deficit                                   (142,987,921)   (133,182,485)
    -------------------------------------------------------------------------
                                                  42,782,174      52,013,031

    Basis of presentation
    Commitments
    -------------------------------------------------------------------------
                                               $  50,806,229   $  63,073,239
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    YM BIOSCIENCES INC.
    Interim Consolidated Statements of Operations and Comprehensive Income
    (Expressed in Canadian dollars)

    -------------------------------------------------------------------------
                         Three months ended             Nine months ended
                              March 31,                     March 31,
                           2009            2008          2009           2008
    -------------------------------------------------------------------------
                            (Unaudited)                   (Unaudited)
    Out-licensing
     revenue      $     776,127  $   1,155,835  $   3,823,296  $   3,438,601
    Interest
     income             201,635        622,029      1,009,323      2,039,663
    -------------------------------------------------------------------------
                        977,762      1,777,864      4,832,619      5,478,264

    Expenses:
      General and
       adminis-
       trative        1,190,039      1,416,872      3,530,626      5,526,388
      Licensing
       and product
       development    3,259,177      4,286,792     11,525,789     12,052,278
    -------------------------------------------------------------------------
                      4,449,216      5,703,664     15,056,415     17,578,666
    -------------------------------------------------------------------------

    Loss before
     the undernoted  (3,471,454)    (3,925,800)   (10,223,796)   (12,100,402)

    Gain on
     foreign
     exchange            51,122         15,584        143,009         29,716

    Gain (loss)
     on short-
     term deposits      (54,507)        91,569        (31,789)       217,985

    Loss on
     disposal
     of property and
     equipment                -              -              -        (70,143)

    Other income              -              -        307,140              -

    -------------------------------------------------------------------------
    Loss and
     comprehensive
     loss for
     the period   $  (3,474,839) $  (3,818,647) $  (9,805,436) $ (11,922,844)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Basic and
     diluted loss
     per common
     share        $       (0.06) $       (0.07) $       (0.18) $       (0.21)

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted
     average
     number of
     common
     shares
     outstanding     55,835,356     55,835,356     55,835,356     55,835,356

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    YM BIOSCIENCES INC.
    Interim Consolidated Statements of Deficit
    (Expressed in Canadian dollars)

    -------------------------------------------------------------------------
                         Three months ended             Nine months ended
                              March 31,                     March 31,
                           2009            2008          2009           2008
    -------------------------------------------------------------------------
                            (Unaudited)                   (Unaudited)

    Deficit,
     beginning
     of period    $(139,513,082) $(126,400,938) $(133,182,485) $(118,296,741)

    Loss for
     the period      (3,474,839)    (3,818,647)    (9,805,436)   (11,922,844)

    -------------------------------------------------------------------------
    Deficit, end
     of period    $(142,987,921) $(130,219,585) $(142,987,921) $(130,219,585)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    YM BIOSCIENCES INC.
    Interim Consolidated Statements of Cash Flows
    (Expressed in Canadian dollars)

    -------------------------------------------------------------------------
                         Three months ended             Nine months ended
                              March 31,                     March 31,
                           2009            2008          2009           2008
    -------------------------------------------------------------------------
                            (Unaudited)                   (Unaudited)

    Cash provided
     by (used in):

    Operating
     activities:
      Loss for
       the period $  (3,474,839) $  (3,818,647) $  (9,805,436) $ (11,922,844)
      Items not
       involving
       cash:
        Amortiza-
         tion of
         property
         and
         equipment       19,806         20,781         57,282        106,364
        Amortiza-
         tion of
         intangible
         assets         265,135        265,135        795,406        795,406
        Loss on
         disposal
         of property
         and
         equipment            -              -              -         70,143
        Unrealized
         loss
         (gain) on
         short-term
         deposits        56,219        (98,443)        33,501        (91,569)
        Stock-based
         compensation   195,023        324,704        574,579      1,827,991
      Change in
       non-cash
       operating
       working
       capital:
        Accounts
         receivable
         and
         prepaid
         expenses       255,258        257,614        (45,639)      (152,916)
        Accounts
         payable,
         accrued
         liabili-
         ties and
         deferred
         revenue       (767,508)      (849,632)    (3,036,153)    (4,204,800)
    -------------------------------------------------------------------------
                     (3,450,906)    (3,898,488)   (11,426,460)   (13,572,225)

    Investing
     activities:
      Short-term
       deposits,
       net            4,233,479     (4,980,923)    17,259,293     10,362,066
      Additions
       to property
       and
       equipment
       and
       intangible
       assets           (19,114)             -        (34,150)       (35,933)
      Proceeds
       from sale
       of property
       and
       equipment              -              -              -         38,996
    -------------------------------------------------------------------------
                      4,214,365     (4,980,923)    17,225,143     10,365,129
    -------------------------------------------------------------------------

    Increase
     (decrease)
     in cash and
     cash
     equivalents        763,459     (8,879,411)     5,798,683     (3,207,096)

    Cash and
     cash
     equivalents,
     beginning
     of period        8,154,413     11,519,666      3,119,189      5,847,351

    -------------------------------------------------------------------------
    Cash and
     cash
     equivalents,
     end of
     period       $   8,917,872  $   2,640,255  $   8,917,872  $   2,640,255
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    %SEDAR: 00004652E




For further information:

For further information: Enquiries: James Smith, the Equicom Group Inc.,
Tel. (416) 815-0700 x 229, Email: jsmith@equicomgroup.com; Thomas Fechtner,
the Trout Group LLC, Tel. (646) 378-2931, Email: tfechtner@troutgroup.com;
Nominated Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050
6500


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890